5-year-old dances through cancer treatment with his epic...
December 14, 2018

CD19 CAR T cell product and disease attributes predict leukemia remission durability

Study results show the potential to prospectively identify patients at risk for therapeutic failure and support the development of approaches to boost CAR T cell activation and proliferation in patients with low levels of CD19 antigen.

A recent study found certain parameters that have the potential to prospectively identify patients at risk for therapeutic failure and support the development of approaches to boost CAR T cell activation and proliferation in patients with low levels of CD19 antigen.

The Journal of Clinical Investigation